Literature DB >> 2839262

Role of bradykinin in the vascular permeability response induced by carrageenin in rats.

S Kumakura1, I Kamo, S Tsurufuji.   

Abstract

1 Bradykinin in carrageenin-induced inflammatory pouch fluid was measured by an enzyme immunoassay method. 2 The bradykinin showed a single peak in the 30-60 min period after the challenge and then decreased quickly, and there was a correlation between the bradykinin level and exudation of fluorescein-labelled bovine serum albumin in the first 60 min period. 3 Captopril (an inhibitor of kininase II) elevated both the bradykinin level in the inflammatory pouch fluid and vascular permeability, while DL-2-mercaptomethyl-3- guanidinoethylthiopropanoic acid (an inhibitor of kininase I) had no effect. 4 Soybean trypsin inhibitor (SBTI) inhibited the vascular permeability response in parallel with the decrease in the bradykinin level. 5 A bradykinin-degrading activity appeared in the pouch fluid within 1 h after the challenge and increased with time. 6 In the period of 3.5-4 h, bradykinin levels were suppressed below the sensitivity limit of the assay, i.e. 0.07 nm ml-1, in spite of active generation. This was because degradation of bradykinin was very rapid in this late stage. Nevertheless, bradykinin still played a definite role in sustaining a high level of vascular permeability response in the late stage in conjunction with prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839262      PMCID: PMC1853887          DOI: 10.1111/j.1476-5381.1988.tb11457.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  A method for the fluorometric assay of histamine in tissues.

Authors:  P A SHORE; A BURKHALTER; V H COHN
Journal:  J Pharmacol Exp Ther       Date:  1959-11       Impact factor: 4.030

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Inhibitory effect of a novel anticomplementary agent, K-76COONa, on the release of histamine induced by zymosan and compound 48/80.

Authors:  S Konno; S Tsurufuji
Journal:  Jpn J Pharmacol       Date:  1985-05

4.  Vascular permeability responses and the role of prostaglandin E2 in an experimental allergic inflammation of air pouch type in rats.

Authors:  N Hirasawa; K Ohuchi; K Sugio; S Tsurufuji; M Watanabe; S Yoshino
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

5.  Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine.

Authors:  M Di Rosa; J P Giroud; D A Willoughby
Journal:  J Pathol       Date:  1971-05       Impact factor: 7.996

6.  Enzyme immunoassay of bradykinin using beta-D-galactosidase as a labeling enzyme.

Authors:  A Ueno; S Oh-ishi; T Kitagawa; M Katori
Journal:  Biochem Pharmacol       Date:  1981-06-15       Impact factor: 5.858

7.  A new sensitive fluorometric method for measurement of vascular permeability.

Authors:  K Watanabe; H Nakagawa; S Tsurufuji
Journal:  J Pharmacol Methods       Date:  1984-06

8.  Second kininase in human blood plasma.

Authors:  H Y Yang; E G Erdös
Journal:  Nature       Date:  1967-09-23       Impact factor: 49.962

9.  [Plasma bradykinin concentration in patients with cardiovascular diseases].

Authors:  M Minami; H Togashi; M Sano; T Endoh; H Saito; F Hashimoto; K Fujita; H Yasuda; Y Kuriyamoto; T Nishino
Journal:  Nihon Yakurigaku Zasshi       Date:  1983-08

10.  Pharmacological analysis of the vascular permeability response in the anaphylactic phase of allergic inflammation in rats.

Authors:  K Ohuchi; N Hirasawa; M Watanabe; S Tsurufuji
Journal:  Eur J Pharmacol       Date:  1985-11-19       Impact factor: 4.432

View more
  9 in total

1.  Potentiation of the pro-inflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws.

Authors:  J Damas; J F Liégeois; W H Simmons
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Kinins and peritoneal exudates induced by carrageenin and zymosan in rats.

Authors:  J Damas; V Bourdon; G Remacle-Volon; A Adam
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

Review 3.  The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation.

Authors:  D F Emerich; R L Dean; C Osborn; R T Bartus
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Effect of treatment with interleukin-1 receptor antagonist on the development of carrageenan-induced pleurisy in the rat.

Authors:  K P Meyers; C L Czachowski; J W Coffey
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

5.  Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats.

Authors:  Danielle R Santos; João B Calixto; Glória E P Souza
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  Influence of histamine on the bradykinin response of canine testicular polymodal receptors in vitro.

Authors:  K Mizumura; M Minagawa; H Koda; T Kumazawa
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

7.  Sensitization of articular afferents to mechanical stimuli by bradykinin.

Authors:  V Neugebauer; H G Schaible; R F Schmidt
Journal:  Pflugers Arch       Date:  1989-12       Impact factor: 3.657

8.  Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain.

Authors:  Stephane R Chartier; Michelle L Thompson; Geraldine Longo; Michelle N Fealk; Lisa A Majuta; Patrick W Mantyh
Journal:  Pain       Date:  2014-09-06       Impact factor: 6.961

9.  Presence of T-kininogen and kinins in sponge-induced exudates in rats.

Authors:  J Damas; A Adam; V Bourdon; G Remacle-Volon
Journal:  Br J Pharmacol       Date:  1989-08       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.